In conclusion, this study provides novel insights into how epigenetic alternations are involved in antitumor immunity modulation and illustrates promising potentials of L1CAM-AS1 in immune-checkpoint inhibitor treatments for HCC. Here, L1CAM is linked to hepatocellular carcinoma.